Eurofins DiscoverX

Great to see much engagement during poster sessions presented at #pegsummit by Alpana Prasad , Jennifer Lin-Jones, & Gaurav Agrawal, Ph.D., on antibody therapeutics & modalities supported by cell based assays. https://lnkd.in/gczXfh3A

🚀Newly Launched Recombinant #GPCRProteins – suited for ligand discovery, structural biology, & MOA studies. Access purified, full-length, functionally validated GPCR proteins - GLP-1R, MRGPRX1, MRGPRX2, APLNR, A2AR, & NK1R implicated in several disorders including obesity. Developed through Eurofins DiscoverX-Eurofins CALIXAR expertise, these proteins are produced using advanced #membraneproteinexpression & #stabilizationtechnologies designed to maintain structural integrity, correct folding, & functional activity. Shop GPCR proteins & advance your drug discovery & development programs! https://lnkd.in/gDRFyvXA

🎤Listening to Jennifer Lin-Jones at #PEGSSummit on mechanistic characterization of Bi- & Multi-specific Antibodies? — a critical topic in antibody #biologics development. Do catch up with the speaker (booth #400) to discuss in depth strategies for developing next-gen #antibodytherapeutics.

🔬 Live at #PEGSummit! Experts from Eurofins DiscoverX are thrilled to connect with the #biologics community. Stop by our booth (#400) to chat about how our #cellbasedassays can accelerate your biologics development — from pre-clinical discovery to GMP validated potency #bioassays. Whether you are working on ADCs, bi- & multi-specific antibodies, or interested in a strategy to characterize agonistic antibodies, the team (Gaurav Agrawal, Ph.D., Dana Haley-Vicente, Ph.D., Alpana Prasad, James Fossetta, Kai Song, Arturo Gonzalez Moya, & Luis Hinojosa Puerta can guide you in the right direction for accelerating your biologics programs.

💡𖣘 The innovation engine continues to run at Eurofins DiscoverX to advance next-gen therapeutics! Learn WHAT’s NEW to accelerate your #drugdiscoverydevelopment programs. What’s inside? - New #GPCR ortholog ready-to-assay eXpress kits & cell line assays (GLP-1R & GIPR) - New GPCR #recombinantproteins (GLP-1R, MRGRPX1/2, APLNR, A2AR, & NK1R) - New stable #celllineassays (IL-11 signaling reporter & VEGFR2/3 dimerization) Access the flyer & reach out (https://lnkd.in/gigM5K7r) if you need more information about any of these new products. 

Heading to #PEGSummit in Boston? We would love to meet you! Visit us at booth #400, learn about #cellbasedassays & #bispecificantibodies (talk & poster), & review #posters on ADCs, checkpoint agonistic antibodies, & more. #ConferenceTalk: Attend Advances in Immunotherapy session (Tuesday, May 12th at 3:30pm) presentation by Jennifer Lin-Jones on how mechanism-driven, cell-based assays can accelerate your bi- & multi-specific #antibodyprograms — from screening all the way through characterization. Learn how Eurofins DiscoverX’s cell-based assay portfolio can help fast track the development of your #antibodytherapeutics by 6 to 9 months. See you there! https://lnkd.in/gczXfh3A #PEGS2026 #Biologics #DrugDevelopment #DiscoverX

Antibody-Drug Conjugates (#ADCs) & bispecific Antibodies (#bsAbs) are two transformative & complementary modalities in #oncology #drugdevelopment. Review two scientific #posters from Eurofins DiscoverX® detailing workflows & formats for the characterization of ADCs & bsAbs using MOA-reflective assays — for smarter candidate selection, optimization, & regulatory-enabling studies. ADC Poster: Integrated Evaluation of Payload-, Fc-, and Target-mediated Mechanisms of ADCs Using Streamlined Complementary Platforms. https://lnkd.in/g8KwD4F9 Bi-specific Antibody Poster: Mechanism-driven Cell-based Assays to Screen & Characterize Bi-specific Antibodies. https://lnkd.in/gnNbNp_p

Exciting to see great interest at the #AACR26 #postersession happening NOW! Connect with Alpana Prasad to learn how a streamlined approach to characterizing antibody-drug conjugates (#ADCs) can accelerate your programs. Stop by poster #6934. https://lnkd.in/gBH5bC-f

Live at #AACR26. Incredible to see the level of engagement at the poster session where Venkatesh Vasu Chari, Ph.D. is currently presenting about bi-specific antibodies (#bisAbs) & their characterization using Eurofins DiscoverX's robust #cellbasedassay portfolio. Stop by Poster #5543 (April 21, 2:00-5:00 PM PST) to learn more about the technology behind characterizing bis-Abs. https://lnkd.in/gBH5bC-f

🧬Accelerate #ubiquitintherapeutics with Eurofins DiscoverX’s newly launched active, purified proteins representing the #ubiquitination cascade. These purified #recombinantproteins, including functionally active E1, E2, & E3 enzymes, allow the study of ubiquitin system in vitro with high confidence & reproducibility to advance these compelling targets for therapeutic intervention & #drugdevelopment. Benefits of Ubiquitin Proteins Portfolio: - Screen E1–E3 activity, validate PROTACs in vitro, & study ubiquitination mechanisms (kinetics, specificity, chain linkages). - Utilize full-length, validated enzymes including active #E3ligases (e.g., VHL, SCF complexes, CRBN) to authenticate protein:protein interactions & study of allosteric inhibitors. Access a broad range of ubiquitn products for therapeutics development, https://lnkd.in/g8jmfJKd